By Spondylitis Association of America
July is Juvenile Arthritis Awareness Month, and we want to give an extra shout-out to both our juvenile spondyloarthritis warriors, and the medical rock stars who care for them: pediatric rheumatologists.
July is Juvenile Arthritis Awareness Month and we want to show our support to kids and teens with spondyloarthritis. In this installment of Community Wisdom, we asked our online community, “What advice or words of encouragement do you have to share?”
It’s a question posed time and again in spondylitis support groups and online community forums – how do you handle your spondyloarthritis in the workplace? Should you tell your employer, or keep your diagnosis private?
A recent Greek cohort study reported that Ankylosing Spondylitis (AS) patients in remission remained in remission after switching from the originator biologic, reference infliximab (Remicade®) to the biosimilar infliximab, (Inflectra®, Remsima®). The 18-month long, open label, observational study found no difference in disease activity, efficacy, or safety in those switched to the biosimilar medication.
On June 25, 2019, SAA hosted our second Twitter chat. The chat focused on advocacy, and featured members of SAA’s Volunteer Advocacy Committee: Rose @funchefchick, Mary Ann @MaryAnnPoladian and Charis @BeingCharisBlog, as well as @RichAHoward, who is SAA’s Chief Mission Advancement Officer, and leads our Los Angeles spondylitis support group.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.